In one analysis, 16% of men with no suspicious lesions on MRI had clinically significant prostate cancer identified after ...
Boston Scientific inks a new agreement to acquire Bolt Medical, developer of Bolt IVL, for approximately $443 million.
ScreenPoint Medical today announced the acquisition of Biomediq A/S, a research-based company focused on the research, ...
Calcipotriol-plus–5-FU therapy activates immune pathways, offering long-lasting protection against squamous cell carcinoma by ...
Artificial intelligence has the potential to improve the analysis of medical image data. For example, algorithms based on deep learning can determine the location and size of tumors. This is the ...
Boston Scientific Corporation (NYSE:BSX) agreed to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy ...
Boston Scientific (NYSE: BSX) announced today that it agreed to acquire intravascular lithotripsy (IVL) platform developer ...
Cervical cancer remains a major health threat for women globally, with the highest incidence in developing nations. Despite ...
Patrick Wood, an analyst from Morgan Stanley, maintained the Buy rating on Boston Scientific (BSX – Research Report). The associated price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback